Dr. Erin Murphy, MD of Cleveland Clinic explains the phase I dose escalation study for neoadjuvant radiosurgery for large brain metastases.
Preoperative (neoadjuvant) stereotactic radiosurgery (SRS) with dose escalation followed by surgical resection for brain metastases > 2 cm yielded local control comparable to that with postoperative SRS or whole-brain radiation therapy (WBRT) — with the benefits of acceptable acute toxicity and a low incidence of leptomeningeal disease.
These preliminary findings from a Cleveland Clinic prospective phase 1/2 clinical trial were presented Sept. 15 at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).
“So far we have seen excellent results with radiation doses higher than the current SRS standards,” says lead investigator Erin Murphy, MD, a radiation oncologist in Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “If findings continue to be positive, we anticipate that new standards can be adopted to safely save more patients from recurring disease.”